NCT03027960 (EMPA) is a Phase 1 clinical trial of Empagliflozin in Heart Failure, sponsored by Yale University.

Who is sponsoring NCT03027960?

NCT03027960 is sponsored by Yale University.

What drugs are being tested in NCT03027960?

Interventions in NCT03027960: Empagliflozin, Placebo Oral Capsule.

What condition does NCT03027960 study?

NCT03027960 studies Heart Failure, Type II; Diabetes.

Is NCT03027960 still recruiting?

NCT03027960 is currently completed. Last updated 26 June 2020.

Last reviewed 2020-06-26 · How we verify

NCT03027960: EMPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Completed Phase 1 Last updated 26 June 2020

What this trial tests

Phase 1 trial testing Empagliflozin in Heart Failure in 21 participants. Completed in 1 June 2019.

Timeline

27 June 2017

Primary endpoint
14 May 2019

1 June 2019

Quick facts

Lead sponsor	Yale University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	21
Start date	27 June 2017
Primary completion	14 May 2019
Estimated completion	1 June 2019
Sites	1 location across United States

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →
Placebo Oral Capsule

Conditions studied

Heart Failure — all drugs for Heart Failure →
Type II; Diabetes — all drugs for Type II; Diabetes →

Sponsor

Yale University

Who can join

18 and older, any sex, with Heart Failure or Type II; Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR \>45ml/min/1.73 m2 who are chronically receiving loop diuretics.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, et al · · 2017 · cited 330× · PMID 29061576 · DOI 10.1161/circulationaha.117.030012
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, et al · · 2020 · cited 312× · PMID 32410463 · DOI 10.1161/circulationaha.120.045691
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, et al · · 2024 · cited 26× · PMID 38073038 · DOI 10.1681/asn.0000000000000269
SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
Singh AK, Singh R. · · 2019 · cited 2× · PMID 31161099 · DOI 10.4103/ijem.ijem_12_19

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03027960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 26 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03027960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing